Vir Biotechnology CFO Jason O'Byrne to depart; interim replacement named

Vir Biotechnology disclosed in an 8-K filing that Jason O'Byrne, Executive Vice President and Chief Financial Officer, told the company on July 20, 2026 that he plans to leave his position, with his departure taking effect on August 3, 2026, in order to take up a different opportunity.¹

The company stated that O'Byrne's decision to resign did not stem from any dispute with Vir Bio over its operations, policies, or practices.¹ Vir Bio has begun looking for someone to succeed him.¹

To fill the gap, the Board of Directors appointed Brent Sabatini, Senior Vice President and Chief Accounting Officer of Vir Bio, as interim "principal financial officer" of the company, effective August 3, 2026.¹

Sabatini's background includes serving as Senior Vice President and Chief Accounting Officer since February 2023 and as the company's "principal accounting officer" since October 2024.¹ He brings more than two decades of relevant experience, having worked at Capsida Biotherapeutics, Inc. from March 2021 to February 2023, most recently as Head of Finance.¹ Before that, he spent from April 2004 to March 2021 at Amgen Inc., moving through roles of increasing responsibility including leadership positions in Accounting, Tax and Financial Planning and Analysis.¹

Sabatini is a Certified Public Accountant who holds a B.S. in Accountancy from California State University, Northridge, and an MBA from the University of Michigan's Stephen M. Ross School of Business.¹

The filing noted that no arrangements or understandings exist between Sabatini and any other parties regarding his selection for the interim role¹, and that he has no family relationships with any director or executive officer of Vir Bio.¹ Additionally, Sabatini has no direct or indirect interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K, and he will not receive any change or addition to his compensation for taking on the interim financial officer duties.¹